论文部分内容阅读
在2013年美国临床内分泌医师学会(AACE)2型糖尿病综合管理指南中,突出的变化强调了体重管理的重要性,因此推荐具有减重效应的GLP-1受体激动剂,成为继二甲双胍之后的首选药物。显然最大的变化是突出了减肥的重要性和GLP-1在治疗策略中的位置。1脂代谢紊乱的重要表达之一非酒精性脂肪肝病(NAFLD)伴随世界现代化的前进,人类的疾病谱也在变化,代谢综合征(MS)发病率正在以惊人的速度在增长,已
In the 2013 American College of Clinical Endocrinologists (AACE) Guidelines for Type 2 Diabetes Mellitus Management, outstanding changes highlighted the importance of weight management and therefore recommend a GLP-1 receptor agonist with a weight-loss effect to be a Preferred drug. Clearly the biggest change highlights the importance of weight loss and the location of GLP-1 in treatment strategies. 1 One of the important expression disorders of lipid metabolism Non-alcoholic fatty liver disease (NAFLD) With the modernization of the world, the disease spectrum of human beings is also changing. The incidence of metabolic syndrome (MS) is increasing at an alarming rate.